glp 1 blue cross Beyond the Buzz: Understanding the GLP-1 Trend GLP-1 | Blue Cross and

This quarter already saw a double-digit revenue growth in the segment as a large gene therapy product whose revenue was treated as development revenue a year ago is now treated as commercial revenue. Catalents largest gene therapy customer is Sarepta Therapeutics, which saw the US Food and Drug Administration (FDA) approve its adeno-associated virus-based gene therapy Elevidys (delandistrogene moxeparvovec) back in June

Yes, semaglutide is considered safe for patients with benign thyroid nodules when medullary thyroid cancer and MEN2 are ruled out by your medical history

GLP-1 Up What's the deal with GLP-1 Medications

Increasing evidence shows that GLP-1 analogs have neuroprotective effects in animal models

reduction in sustained decline in eGFR, kidney disease progression or end-stage kidney disease) and the tolerability of SGLT2is across the CKD spectrum [10,11,12]

We look forward to receiving your contributions to the Special Issue